NEWARK, Del. According to Future Market Insights, the global zoonotic antivirals market is valued at USD 2.5 billion in 2026 and is projected to reach USD 6.6 billion by 2036, expanding at a 10.2% CAGR from 2026 to 2036. Market demand is being shaped by outbreak preparedness, surveillance at the human-animal interface, strategic stockpiling, and the need for antiviral agents that can be rapidly deployed against emerging and re-emerging zoonotic viruses. The report cites the World Health Organization's 2024 research and development blueprint for epidemics, which identifies priority zoonotic viral diseases as part of global preparedness planning.

👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-31263

Global Segment Leaders

• Products – Broad-spectrum antivirals: 48.0% share — Broad-spectrum agents lead because they can be deployed during the early stages of an outbreak when viral identity and mutation profiles remain uncertain.
• Applications – Emerging zoonoses: 56.0% share — Emerging zoonoses account for the largest application share because unpredictable spillover events and limited preexisting immunity require rapid antiviral readiness.
• End User – Government stockpiles: 46.0% share — Government stockpiles dominate utilization because centralized procurement supports preparedness, inventory management, and rapid distribution during outbreaks.

Country-Level Performance

·         India – 11.9% CAGR (2026–2036): Expanded zoonotic surveillance coverage, government-led strategic stockpiling, hospital formulary alignment, and strong domestic manufacturing capacity.

·         China – 11.7% CAGR (2026–2036): Integrated national surveillance systems, centralized procurement, state-supported manufacturing, and research collaboration on broad-spectrum agents.

·         Brazil – 11.4% CAGR (2026–2036): Biodiversity-linked spillover risk management, federal contingency planning, local production through technology transfer, and expanded regional laboratory capacity.

·         USA – 10.8% CAGR (2026–2036): Strategic national stockpile maintenance, hospital response protocols, advanced surveillance and genomic monitoring, and public-private manufacturing partnerships.

·         UK – 9.7% CAGR (2026–2036): Centralized health-security procurement, NHS formulary alignment, research funding for antiviral effectiveness, and managed access frameworks.

The report specifically profiles these five country markets, with India recording the highest CAGR at 11.9% and the UK the lowest at 9.7%.

Regional Context

Fast-growing markets: India, China, and Brazil record the three highest country growth rates at 11.9%, 11.7%, and 11.4%, respectively. India's expansion is linked to broader surveillance across livestock, wildlife, and urban interfaces, government stockpiling, and domestic pharmaceutical capacity. China's growth reflects integrated surveillance and centralized procurement, while Brazil's market benefits from biodiversity-related spillover management, contingency planning, technology-transfer agreements, and expanded laboratory capacity.

Moderate-growth market: The USA records a 10.8% CAGR, with demand driven by strategic national stockpile maintenance, federal preparedness frameworks, genomic surveillance, hospital response protocols, and public-private manufacturing partnerships.

Slower-growing profiled market: The UK records a 9.7% CAGR. Growth is supported by centralized health-security planning, coordinated procurement and distribution, NHS formulary alignment, research funding, and managed-access mechanisms balancing preparedness and cost.

The full report covers Asia Pacific, Europe, North America, Latin America, and the Middle East & Africa, with country coverage spanning India, China, Brazil, the USA, the UK, and 40+ countries.

Market Drivers, Restraints and Opportunities

The increasing recognition of viral diseases transmitted between animals and humans is supporting demand for antiviral preparedness. The report highlights influenza A viruses, certain coronaviruses, and zoonotic flaviviruses as continuing spillover risks. Public-health and hospital procurement teams evaluate antiviral spectrum, resistance profiles, pharmacokinetics, shelf life, and deployment requirements when building preparedness programs.

Preparedness-oriented procurement is a defining feature of the market. Unlike conventional infectious-disease therapeutics, purchasing is often linked to surveillance alerts, risk assessments, strategic stockpiles, and policy mandates. Government buyers can negotiate volume commitments in advance, while hospitals activate antiviral inventories when case confirmation and treatment protocols align.

Clinical and development uncertainty remains a restraint. Sporadic outbreaks can make clinical-trial recruitment difficult, while accelerated or emergency regulatory pathways can create post-authorization evidence requirements. Manufacturers must also balance surge-production capacity against the risk of inventory becoming obsolete when anticipated outbreaks do not occur.

Broad-spectrum platforms present an opportunity because they can retain utility across multiple potential outbreak scenarios. FMI notes that capital allocation is increasingly directed toward mechanisms conserved across viral families, while surveillance and diagnostics can support targeted deployment as pathogen identity becomes clearer.

Competitive Landscape

The key companies profiled by FMI are Gilead Sciences, Roche, Pfizer, Merck, and Johnson & Johnson. Gilead Sciences is positioned around antiviral platforms with established efficacy and scalable manufacturing for emergency demand. Roche combines antiviral and diagnostic capabilities, while Pfizer brings oral antiviral products, global commercialization capabilities, and experience with emergency authorizations. Merck contributes antiviral research depth and established public-sector relationships, while Johnson & Johnson participates through diversified infectious-disease capabilities and supply reliability across multiple geographies.

Competitive differentiation centers on speed to scale, resistance management, access frameworks, manufacturing resilience, stockpile stability, regulatory readiness, and coordination with outbreak-response systems. Procurement decisions also consider advance-purchase agreements, shelf-life predictability, quality documentation, cold-chain requirements, and global distribution reach.

The current FMI report page does not publish a dated “Key Developments” subsection for these companies; therefore, no company-specific development has been added to this release.

Regional Market Coverage

The report evaluates zoonotic antiviral demand across North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and the Middle East & Africa. The detailed country framework includes markets such as the USA, Canada, Mexico, Brazil, Chile, Germany, the UK, Italy, Spain, France, China, Japan, South Korea, India, Australia & New Zealand, ASEAN, Saudi Arabia, Turkiye, and South Africa.

Access Full Report: https://www.futuremarketinsights.com/reports/zoonotic-antivirals-market

Report Scope

The Zoonotic Antivirals Market report covers:

• Products: Broad-spectrum antivirals, Targeted antivirals, Combination therapies
• Applications: Emerging zoonoses, Endemic zoonotic infections
• End User: Government stockpiles, Hospitals, Research institutes
• Regions: Asia Pacific, Europe, North America, Latin America, Middle East & Africa
• Countries: India, China, Brazil, USA, UK, and 40+ countries
• 2026 Market Size: USD 2.5 billion
• 2036 Forecast: USD 6.6 billion
• CAGR: 10.2%
• Forecast Period: 2026–2036
• Key Companies: Gilead Sciences, Roche, Pfizer, Merck, Johnson & Johnson

Related Reports:

·         https://www.newstrail.com/neurorehabilitation-technology-market-to-reach-usd-2-86-billion-by-2036-at-8-1-cagr/

·         https://www.newstrail.com/organ-transplant-donor-derived-cell-free-dna-monitoring-market-to-reach-usd-1-09-billion-by-2036/

·         https://www.newstrail.com/pharma-peeler-centrifuge-market-to-reach-usd-1-44-billion-by-2036-at-6-1-cagr/

·         https://www.fmiblog.com/2026/09/29/cardiovascular-drug-discovery-market-to-reach-usd-2-93-billion-by-2036-at-8-6-cagr/

·         https://www.fmiblog.com/2026/09/29/clinical-stage-cardiovascular-therapeutics-market-to-reach-usd-2-43-billion-by-2036-at-7-8-cagr/

About Future Market Insights

Future Market Insights (FMI) is a leading provider of market research and consulting services, offering syndicated and customized research across industries including healthcare, chemicals and materials, and pharmaceuticals.

For Press & Corporate Inquiries

Rahul Singh
AVP – Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075

For Sales – sales@futuremarketinsights.com
For Media – Rahul.singh@futuremarketinsights.com
For Web – https://www.futuremarketinsights.com